Safety and Effectiveness of Two Different Formulations of an HIV Vaccine in Infants Born to HIV-Infected Women
Phase 1
Withdrawn
- Conditions
- HIV InfectionsHIV Seronegativity
- Registration Number
- NCT00000809
- Brief Summary
The purpose of this study is to test the safety and effectiveness of two different formulations of an HIV vaccine in infants born to HIV-infected women.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- WITHDRAWN
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie the immunogenicity of MN rsgp120/HIV-1 with QS-21 and Alum adjuvants in HIV-exposed infants?
How does the safety profile of MN rsgp120/HIV-1 with QS-21 and Alum compare to standard-of-care HIV prophylaxis in neonates?
Which biomarkers correlate with immune response to HIV vaccine formulations in NCT00000809 clinical trial infants?
What adverse events are associated with QS-21 adjuvant use in HIV-1 vaccine trials for neonatal populations?
How do MN rsgp120/HIV-1 vaccine formulations compare to other gp120-based HIV vaccines in pediatric immunogenicity studies?